Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for difluprednate ophthalmic emulsion 0.05% from the United States Food and Drug Administration (FDA).Cipla's difluprednate ophthalmic emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation's Durezol.It is used for the treatment of inflammation and pain associated with ocular surgery and treatment of endogenous anterior uveitis.According to IQVIA (IMS Health), Durezol had US sales of approximately $106 million for the 12-month period ending June 2021.The product will be available for shipping soon.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!